The chemical company's $135m corporate venturing fund targets companies developing technology based around health, nutrition, resource efficiency, and globalisation, according to its managing director.
Germany-based specialty chemicals producer Evonik will follow up its investments in three early-stage companies this year by seeking out additional businesses that fit the strategic megatrends in which it is interested, Bernard Mohr, managing director of Evonik Venture Capital, told Global Corporate Venturing.
Evonik formed its €100m ($135m) venture capital fund in early 2012, hiring Mohr from chemical company BASF. Its latest portfolio company is biodegradable lubricant producer Biosynthetic Technologies, in which it invested in last month alongside petroleum company…
